Management is actually pretty good. The cholesterol drug failure really put some the scare on them. Personally, I didn't think the company would survive and daresay it almost didn't. Management took a haircut, should have taken a bigger one, but their comms since then have been great.
But this is a positive announcement and very good to have multiple shots on goal with this compound.
It's still just a gamble, they have no pipeline or plan B, probably a 5% chance of actually making it to P3. But that's better than most biotechs on the ASX, haha.
On the negative side, having someone with genuine psychiatric problems like Bendunstan cheerleading them on, does make me think twice about investing more... you know what I mean? If someone clearly that stupid thinks it's a good investment, something is definitely amiss.
Anyway, good luck everyone!
NYR Price at posting:
10.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)